经皮椎体强化术治疗中上胸椎骨质疏松性压缩骨折疗效分析

摘要

Objective To evaluate the efficacy of percutaneous vertebral augmentation (PVA) in treatment of mid- and upper thoracic osteoporotic vertebral compression fractures (OVCF). Methods From June 2007 to May 2011), twenty-nine patients who underwent PVA for OVCFs in the mid- and upper thoracic spine (above T8 thoracic spine) were retrospectively reviewed. Outcome measures including bone mineral density, severity of the fracture vertebral above the T8, average amount of bone cement injected, method of vertebral augmentation (PVP or PKP) and observed complications. The score changes of visual analogue scale (VAS) and O'Brien activity score preoperative, 3 days. 1 month and 3 months after surgery were recorded. Results All of the 29 patients were followed up for at least 6 months, 9 vertebras experienced bone cement leakage. 4 patients experienced new VCFs during the follow-up period. Compared the patients' VAS score of pain intensity evaluation and the activity score of 3 days, 1 month and 3 months after surgery with preoperative, there was significant difference (P<(). 05). Conclusions PVA is a safe and effective technique for mid- and upper thoracic OVCFs.%目的 探讨经皮椎体强化术治疗中上胸椎骨质疏松性压缩骨折的疗效.方法 回顾性研究2007年6月至2010年5月经椎体强化术治疗的29例中上胸椎骨质疏松性压缩骨折患者.观察指标包括骨密度值、Ts以上椎体骨折严重程度、平均骨水泥注入量、椎体强化术术式,并观察并发症情况.记录术前、术后3d、术后1个月、术后3个月患者疼痛视觉模拟评分(VAS)及O’Brien活动能力评分变化情况.结果 29例患者经至少6个月随访,37个T8以上椎体中发生骨水泥渗漏有9个,4例患者在随访期间出现新发椎体骨折.患者术后3d、1个月、3个月VAS评分和O’Brien活动能力评分与术前相比,差异均有统计学意义(P＜0.05).结论 经皮椎体强化术治疗中上胸椎骨质疏松性椎体压缩骨折安全、有效.